Jose Vindas Cordero
Jacksonville, FLNPI 1326050105
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,325 of the $43,669 with a category attached, or 71.7%. Viiv Healthcare Company accounts for 81.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $19,506 and has fallen 99.4% since, to $124 in 2025.
Across 384 payments — averaging $113.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$36K
- Gilead$2K
- GSK$1K
- Merck$1K
- AbbVie$926
- Insmed, Inc.$839
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$31,32572%
- Travel & lodging$2,2695%
- Food & beverage$9,58322%
- Education$4931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 120 | $35,742 |
| Gilead | 48 | $1,894 |
| GSK | 9 | $1,047 |
| Merck | 51 | $1,033 |
| AbbVie(2 entities) | 37 | $926 |
| Insmed, Inc. | 29 | $839 |
| Janssen Products, LP | 7 | $599 |
| Johnson & Johnson | 43 | $559 |
| Melinta Therapeutics, LLC | 8 | $243 |
| Shionogi Inc | 5 | $163 |
| Smith+Nephew | 5 | $159 |
| Theratechnologies Inc. | 10 | $159 |
| Boston Scientific | 1 | $125 |
| Nabriva Therapeutics, PLC | 4 | $62 |
| Grifols USA, LLC | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Reddress USA, Inc. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Organogenesis Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dicloxacillin Sodium | 12 | $982 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.